Niklas Loman
41 – 50 of 123
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients
(
- Contribution to journal › Article
- 2016
-
Mark
Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer.
(
- Contribution to journal › Article
-
Mark
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
(
- Contribution to journal › Article
-
Mark
Is Breast-conserving Therapy Really a Good Option for BRCA1/2 Mutation Carriers?
(
- Contribution to journal › Article
-
Mark
The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic
(
- Contribution to journal › Article
-
Mark
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women
(
- Contribution to journal › Article
- 2015
-
Mark
Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers.
(
- Contribution to journal › Article
-
Mark
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
(
- Contribution to journal › Article
-
Mark
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.
(
- Contribution to journal › Article